These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3873304)

  • 81. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
    Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
    Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Heavy and light chain utilization in autoantibodies of elderly patients with systemic lupus erythematosus.
    Ward MM; Pisetsky DS
    Clin Immunol Immunopathol; 1990 Nov; 57(2):280-96. PubMed ID: 2208808
    [TBL] [Abstract][Full Text] [Related]  

  • 83. DNA antibodies with and without complement-binding ability.
    Teppo AM; Kurki P; Helve T; Wegelius O
    Rheumatol Int; 1984; 4(4):173-6. PubMed ID: 6484446
    [TBL] [Abstract][Full Text] [Related]  

  • 84. In vitro immune response of SLE lymphocytes. The mechanism involved in B-cell activation.
    Takeuchi T; Abe T; Kiyotaki M; Toguchi T; Koide J; Morimoto C; Homma M
    Scand J Immunol; 1982 Nov; 16(5):369-77. PubMed ID: 6758109
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.
    Rondaan C; van Leer CC; van Assen S; Bootsma H; de Leeuw K; Arends S; Bos NA; Westra J
    Lupus; 2018 Jul; 27(8):1271-1278. PubMed ID: 29667858
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity.
    Pruzanski W; Goulding NJ; Flower RJ; Gladman DD; Urowitz MB; Goodman PJ; Scott KF; Vadas P
    J Rheumatol; 1994 Feb; 21(2):252-7. PubMed ID: 8182633
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Human lupus monoclonal autoantibodies bind to Raji cells.
    Shoenfeld Y; Smorodinsky NI; Lavie G; Hazaz B; Joshua H; Pinkhas J
    Immunol Lett; 1985; 11(2):121-6. PubMed ID: 4086063
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Frequency of anti-DNA antibody producing cells from normals and patients with systemic lupus erythematosus.
    Hoch S; Schur PH; Schwaber J
    Clin Immunol Immunopathol; 1983 Apr; 27(1):28-37. PubMed ID: 6307568
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Cellular regulation of anti-nRNP antibody synthesis is different from that of anti-DNA antibody synthesis in patients with systemic lupus erythematosus.
    Hosono O; Takeuchi T; Koide J; Takano M; Abe T
    Rheumatol Int; 1988; 8(4):177-83. PubMed ID: 3263692
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In vitro production of an anti-DNA idiotype by lymphocytes of normal subjects and patients with systemic lupus erythematosus.
    Datta SK; Naparstek Y; Schwartz RS
    Clin Immunol Immunopathol; 1986 Mar; 38(3):302-18. PubMed ID: 2417769
    [TBL] [Abstract][Full Text] [Related]  

  • 91. DNA antibodies and complement in SLE patients. A follow-up study.
    Helve T; Kurki P; Teppo AM; Wegelius O
    Rheumatol Int; 1983; 3(3):129-32. PubMed ID: 6608131
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Characterization of the spontaneous DNA-synthesizing and/or IgG-secreting cells in peripheral blood from patients with systemic lupus erythematosus.
    Yano K; Morimasa K; Asano T; Shinohara Y; Ota Z
    Clin Immunol Immunopathol; 1985 Apr; 35(1):57-66. PubMed ID: 3873305
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Lack of natural antibodies in rheumatic diseases.
    Bijlsma JW; Plater-Zyberk C; Mumford P; Maini RN
    Rheumatol Int; 1990; 10(3):107-12. PubMed ID: 1697425
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity.
    Wigfall DR; Sakai RS; Wallace DJ; Jordan SC
    Clin Immunol Immunopathol; 1988 Jun; 47(3):354-62. PubMed ID: 3131053
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Studies of autologous mixed lymphocyte reactions in patients with systemic lupus erythematosus.
    Russell PJ; Doolan TJ; Webb J; Carr GA
    Pathology; 1983 Jan; 15(1):37-43. PubMed ID: 6134267
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Systemic lupus erythematosus sera inhibit antigen presentation by macrophages to T cells.
    Brozek CM; Hoffman CL; Savage SM; Searles RP
    Clin Immunol Immunopathol; 1988 Feb; 46(2):299-313. PubMed ID: 3257427
    [TBL] [Abstract][Full Text] [Related]  

  • 97. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus.
    Zhou Y; Yuan J; Pan Y; Fei Y; Qiu X; Hu N; Luo Y; Lei W; Li Y; Long H; Sawalha AH; Richardson B; Lu Q
    Clin Immunol; 2009 Sep; 132(3):362-70. PubMed ID: 19520616
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Nature of IgG anti-lymphocyte autoantibody-reactive molecules shed from activated T cells in systemic lupus erythematosus.
    Minota S; Winfield JB
    Rheumatol Int; 1988; 8(4):165-70. PubMed ID: 3055216
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Carbohydrate specificity of IgM autoantibodies to CD45 in systemic lupus erythematosus.
    Fernsten PD; Czyzyk JK; Mimura T; Winfield JB
    Mol Biol Rep; 1994; 20(2):85-95. PubMed ID: 7536298
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Human CD4-reactive antibodies from SLE patients induce reversible inhibition of polyclonal T lymphocyte proliferation.
    Lenert G; Lenert P
    Hum Immunol; 1996 Sep; 49(2):113-21. PubMed ID: 8872165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.